Literature DB >> 2411230

Anti-intermediate filament antibodies, antikeratin antibody, and antiperinuclear factor in rheumatoid arthritis and infectious mononucleosis.

P K Kataaha, S M Mortazavi-Milani, G Russell, E J Holborow.   

Abstract

Sera from patients with rheumatoid arthritis (RA), patients with infectious mononucleosis (IM), and blood donors were tested by indirect immunofluorescence for the presence of antikeratin antibody (AKA), antibody to cytoskeletal intermediate filaments of prekeratin or vimentin type (AIFA) and antiperinuclear factor (APF). In 81.9% of the RA sera and 92.5% of the IM sera AIFA of IgM class was found at titres up to and in some cases exceeding 1/160. In blood donors the incidence of AIFA was 26%, at titres not exceeding 1/20. AKA and APF, always of IgG class, were found in 54.2% and 73.6% of rheumatoid sera. A weak correlation was found in RA between the incidence of AIFA and APF. AKA was not present in either IM or blood donor sera, and APF was found in only 2.5% and 3.2% of IM or blood donors respectively.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2411230      PMCID: PMC1001674          DOI: 10.1136/ard.44.7.446

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  14 in total

1.  Autoantibody to "intermediate filament" in infectious mononucleosis.

Authors:  E Linder; P Kurki; L C Andersson
Journal:  Clin Immunol Immunopathol       Date:  1979-12

2.  All classes of intermediate filaments share a common antigenic determinant defined by a monoclonal antibody.

Authors:  R M Pruss; R Mirsky; M C Raff; R Thorpe; A J Dowding; B H Anderton
Journal:  Cell       Date:  1981-12       Impact factor: 41.582

3.  Anti-keratin antibodies in rheumatoid arthritis.

Authors:  B J Young; R K Mallya; R D Leslie; C J Clark; T J Hamblin
Journal:  Br Med J       Date:  1979-07-14

4.  Antiperinuclear factor and keratin antibodies in rheumatoid arthritis.

Authors:  G D Johnson; A Carvalho; E J Holborow; D H Goddard; G Russell
Journal:  Ann Rheum Dis       Date:  1981-06       Impact factor: 19.103

5.  The antiperinuclear factor. 1. The diagnostic significance of the antiperinuclear factor for rheumatoid arthritis.

Authors:  I R Sondag-Tschroots; C Aaij; J W Smit; T E Feltkamp
Journal:  Ann Rheum Dis       Date:  1979-06       Impact factor: 19.103

6.  Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity.

Authors:  M B Mathews; R M Bernstein
Journal:  Nature       Date:  1983 Jul 14-20       Impact factor: 49.962

7.  Reactivity of serum antibodies to the keratin layer of rat esophagus in patients with rheumatoid arthritis.

Authors:  F P Quismorio; R L Kaufman; T Beardmore; E S Mongan
Journal:  Arthritis Rheum       Date:  1983-04

8.  Antibodies to cytoplasmic intermediate filaments in rheumatic diseases.

Authors:  P Kurki; T Helve; I Virtanen
Journal:  J Rheumatol       Date:  1983-08       Impact factor: 4.666

9.  Antibody to intermediate filaments of the cytoskeleton.

Authors:  O A Osung; M Chandra; E J Holborow
Journal:  Ann Rheum Dis       Date:  1982-02       Impact factor: 19.103

10.  Messenger RNA is translated when associated with the cytoskeletal framework in normal and VSV-infected HeLa cells.

Authors:  M Cervera; G Dreyfuss; S Penman
Journal:  Cell       Date:  1981-01       Impact factor: 41.582

View more
  25 in total

1.  Antibodies to T- and L-isoforms of the cytoskeletal protein, fimbrin, in patients with systemic lupus erythematosus.

Authors:  E C De Mendonca Neto; A Kumar; N A Shadick; A M Michon; P Matsudaira; R B Eaton; P Kumar; P H Schur
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

Review 2.  Polyreactive antibodies in adaptive immune responses to viruses.

Authors:  Hugo Mouquet; Michel C Nussenzweig
Journal:  Cell Mol Life Sci       Date:  2011-11-02       Impact factor: 9.261

3.  Antikeratin antibody in rheumatoid and psoriatic arthritis.

Authors:  C Cooper; D W Cotton; S K Jones; M I Cawley; B J Young
Journal:  Ann Rheum Dis       Date:  1986-04       Impact factor: 19.103

4.  The rheumatoid arthritis-associated autoantibodies to filaggrin label the fibrous matrix of the cornified cells but not the profilaggrin-containing keratohyalin granules in human epidermis.

Authors:  M Simon; C Vincent; M Haftek; E Girbal; M Sebbag; V Gomès-Daudrix; G Serre
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

5.  The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies.

Authors:  M Sebbag; M Simon; C Vincent; C Masson-Bessière; E Girbal; J J Durieux; G Serre
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

6.  Epstein-Barr virus-induced autoimmune responses. I. Immunoglobulin M autoantibodies to proteins mimicking and not mimicking Epstein-Barr virus nuclear antigen-1.

Authors:  J H Vaughan; J R Valbracht; M D Nguyen; H H Handley; R S Smith; K Patrick; G H Rhodes
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

7.  Reaction of antibodies to rheumatoid arthritis nuclear antigen with a synthetic peptide corresponding to part of Epstein-Barr nuclear antigen 1.

Authors:  P J Venables; T Pawlowski; P A Mumford; C Brown; D H Crawford; R N Maini
Journal:  Ann Rheum Dis       Date:  1988-04       Impact factor: 19.103

8.  Anti-cardiolipin antibodies in infectious mononucleosis react with the membrane of activated lymphocytes.

Authors:  R Misra; P J Venables; C Plater-Zyberk; P F Watkins; R N Maini
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

9.  The perinuclear factor, a rheumatoid arthritis-specific autoantigen, is not present in keratohyalin granules of cultured buccal mucosa cells.

Authors:  R M Hoet; R A Voorsmit; W J Van Venrooij
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

10.  Occurrence of antiperinuclear, antikeratin, and anti-RA 33 antibodies in juvenile chronic arthritis.

Authors:  C Gabay; A M Prieur; O Meyer
Journal:  Ann Rheum Dis       Date:  1993-11       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.